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1. Introduction
According to WHO technical report in 1994, osteoporosis is a disease characterized by low
bone mass and microarchitectural deterioration of bone tissue leading to enhanced bone
fragility, and consequently increases the fracture risk. Since fracture does not solely depend
on bone mass, osteoporosis was defined by NIH as a skeletal disorder, characterized by
compromised bone strength predisposing to an increased risk of fracture. Although aging is
a major risk for fracture, it is a strong risk for chronic kidney disease (CKD) as well. Thus,
patients having comorbidity of CKD and osteoporosis are sometimes found. According to a
study NHANES III (the Third National Health and Nutrition Examination Survey, 1988-1994)
in the US, in women with osteoporosis, 85% (95%CI: 79-91%) showed Creatinine clearance
(Ccr)≤60mL/min and 24% (95%CI: 19-29%) were of Ccr<35mL/min [1]. Another study dem‐
onstrated that Ccr≤60mL/min is an independent risk factor for fracture at vertebra, femur and
radius [2].
In addition to aging, a female sex, low bone mineral density (BMD), prevalent fracture, family
history of fracture and lower body weight, life style such as drinking, smoking and excise and
common diseases would affect risk for fracture [3, 4]. Recent studies demonstrate that
measurement of BMD by Dual-energy X-ray absorptiometry (DXA), which is a gold standard
for diagnosis of osteoporosis, is less useful for the fracture prediction in the patients with
diabetes mellitus and the patients under glucocorticoid therapy [5-8]. Among these popula‐
tion, BMD-independent bone fragility and falls may be involved in an elevation of the risk for
fracture. Therefore, much interest is focused on the link between kidney dysfunction /CKD
and fracture /osteoporosis [9].
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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2. Elevated risk for fracture in end-stage kidney disease
Compared with general population, the risk for fracture is reported to be much higher in end-
stage kidney disease (ESKD) (Table 1) [10-14]. A multicenter cohort study in the US having
more than 320,000 dialysis patients, 13.6 in women and 7.5 in men had an incident hip fracture
among 1,000 person-years [10].The incidence ratio standardized with age was about 4.4 times
higher than that of healthy subjects. Another study in a single institution in the US having
1,272 dialysis patients, 13.9 (24.1 in women and 11.7 in men) had an incident hip fracture among
1,000 person-years, which was 17.4 times higher than that of general population [11]. Increased
risk of hip fracture was shown among Japanese hemodialysis (HD) patients, in which the risk
was about 5 times higher than that of general population [12]. Facture risk of HD patients was
increased in the west part of Japan, which showed similar results to the general population [12,
15]. A multicenter prospective study (DOPPS II) in 12,782 patients from 12 countries showed
that 8.9/1,000 person-years had a hip fracture [13]. In addition, risk for fracture may even be
higher for 3 years after kidney transplantation [16].
CKDにおける骨折リスク
Study design Subjects Fracture type Fracture incidence of 1,000 person-years and RR (95%CI) for general population Reference
Retrospective
cohort study
326,464 dialysis patients 
in the US hip
men 7.45 4.44 (4.16-4.75)
women 13.63        4.40 (4.17-4.64) [10]
Retrospective
cohort study
1,272 dialysis patients in 
the US hip
men                  11.7 14.2 (9.3-28.6)
women 24.1         17.2 (7.1-19.4)
all 13.9 17.4 (12.4-34.0)
[11]
Prospective
cohort study
12,782 HD patients in 320 
HD facilities from 12 
countries
hip
any
men, 15-54                       1.00 (Ref)
men, 55-64                       2.15 (1.06-4.57)
men, 65-74                       2.38 (1.07-5.26)
men, 75- 5.05 (2.36-10.82)
women, 15-54                  0.85 (0.30-2.35)
women, 55-64                  1.85 (0.75-4.59)
women, 65-74                  4.67 (2.22-9.83)
women, 75- 7.79 (3.69-16.43)
all                     8.9 (8.4-9.4)
men, 15-54                       1.00 (Ref)
men, 55-64                       1.25 (0.84-1.85)
men, 65-74                       1.65 (1.10-2.48)
men, 75- 1.86 (1.24-2.77)
women, 15-54                  1.07 (0.67-1.69)
women, 55-64                  2.36 (1.56-3.54)
women, 65-74                  2.58 (1.79-3.63)
women, 75- 3.43 (2.33-5.06)
all                    25.6 (24.4-27.0)
[13]
Retrospective
cohort study
128,141 HD patients in 
Japan hip
men 7.57 6.2 (5.7-6.8)
women 17.43        4.9 (4.6-5.3) [12]
         
Table 1. Elevated fracture risk in ESKD
Mean age of incident fracture in dialysis patients is reported to be 61.4 in women and 64.4 in
men, which are much younger than those of general population (74 and 80, respectively),
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indicating that dialysis patients apt to suffer from bone fractures at younger age [11]. The
incidence of hip fracture in dialysis patients of 60 and 70 years old is comparable to those of
75 and 80 years, respectively [13, 14].
CKD is not only at risk for fracture but also at mortality risk after fracture [11, 17, 18]. Coco et
al. reported the mortality rate was 64% a year after hip fracture in HD patients, whereas it was
about 20% in the healthy subjects [11]. Among HD patients, mortality rate was showed to be
2.7 times greater in patients with incident fracture, compared to those without fracture [17].
Moreover, significant elevation of fracture-associated mortality risk was found in patients even
before the initiation of HD therapy [18].Although bisphosphonates may not be recommended
in ESKD patients, they are useful in osteoporotic patients with great risk reduction for fracture
[19]. PTH agent such as teriparatide, and selective estrogen receptor modulator (SERM) are
also established therapies with 50% or more of relative risk reduction [20, 21].Thus, early starts
of therapy for osteoporosis will prevent fracture. These findings suggest that clinicians need
to evaluate bone status and initiate osteoporosis therapy in patients with CKD in early stages.
3. Elevated risk for fracture in early stages of CKD
Although considerably high risk for fracture has been shown in ESKD patients, recent
epidemiological studies indicate that the risk for fracture is elevated in CKD patients, even in
early stages (Table 2). Nickolas et al. reported that CKD was an independent predictor of
prevalent hip fracture [22]. When categorized 6,270 participants by estimated glomerular
filtration rate (eGFR) using MDRD formula, prevalent hip fracture was found in 5.2% and 2.0%
of those with eGFR 15-60mL/min/1.73m2and eGFR>60mL/min/1.73m2, respectively. Odds ratio
of prevalent hip fracture in those with CKD was 2.12 (95%CI: 1.18-3.80), compared with those
with eGFR>100mL/min/1.73m2. Multiple logistic analysis for prevalent hip fracture showed
that osteoporosis (OR=2.52, 95%CI: 1.08-5.91), low activity (OR=2.10, 95%CI: 1.03-4.27) and
CKD (OR=2.32, 95%CI: 1.13-4.74) were the risk factors independent of age, sex, body weight,
race, BMD, history of hip fracture in mother, dietary calcium intake, and 25(OH)D blood level
and propensity score to CKD. In ≥75 years subjects with and without prevalent fracture, the
ratio of CKD suffered was 32.1% and 32.2%, respectively, whereas in < 75 years subjects, the
ratio was 19.2% and 6.2%, respectively. This finding suggests that the younger patients with
prevalent fractures suffer from CKD almost 3 times more frequently, compared to those
without fractures. Thus, CKD (eGFR: 15-60mL/min/1.73m2) is an independent risk of hip
fracture, especially in subjects with <75 years old.
Ensrud et al. conducted a prospective study to examine risk for fracture in 9,704 women with
>65 years, stratified by CCr (Cockcroft-Gault formula) corrected with body surface area [23].
During 6 years observational period, hazard ratios of hip fracture were 2.32 (95%CI: 1.15-4.68)
in CCr<45 mL/min/1.73m2 and 1.57 (95%CI: 0.89-2.76) in CCr45-59 mL/min/1.73m2, compared
to CCr≥60 mL/min/1.73m2. These results suggest that decreased kidney function is a risk for
incident hip fracture independent of age, body weight and calcaneal BMD. However, signifi‐
cant difference disappeared after adjustment by healthy status, smoking, walking excise,
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diabetes mellitus (DM), and history of fracture occurred after 50 years old. On the other hand,
only a tendency was observed using eGFR by MDRD formula instead of CCr. Moreover, the
analysis of fracture sites shows that the risk for fracture was elevated at the trochanter not at
the femoral neck, indicating that hip fracture in CKD patients could be associated with the
frailty [24].
Since sarcopenia or protein-energy wasting (PEW) is commonly seen in CKD patients, eGFR
derived from creatinine often underestimates actual kidney function. Cystatin C is more
accurate estimate for kidney function than eGFR calculated from creatinine, especially in
elderly people whose muscle mass is reduced. Fried et al. demonstrated a significant associa‐
tion between cystatin C blood level and hip fracture risk in 4,699 subjects in their prospective
study. Women with eGFR<60 mL/min/1.73m2 have an increased risk for fracture even after
adjusting the covariates [25].
So far, few studies are performed to evaluate the relationship between kidney function and
vertebral fractures. In a case-control study of 659 postmenopausal osteoporotic women with
an average age of 64.5 years, 45.3% of those with eGFR<60 mL/min/1.73m2 had prevalent
vertebral fractures and the ratio was significantly higher than those with eGFR 60-89 mL/min/
1.73m2 (25.3%) and eGFR≥90 mL/min/1.73m2 (23.8%) [26]. Multiple logistic regression analysis
showed that CCr was selected as a significant predictor of prevalent vertebral fracture after
CKDにおける骨折リスク
Study 
design Subjects Kidney function Odds ratio of fracture risk (95%CI) Reference
Cross-
sectional 
study
5313 osteoporotic patients 
aged >65 in Germany CCr＜65mL/min
hip 1.57 (1.18–2.09)
radius 1.79 (1.39–2.31)
vertebra 1.31 (1.19–1.55)
[2]
Cross-
sectional 
study
6270 subjects aged >50 in 
the US eGFR＜60mL/min/1.73m
2 hip 2.32 (1.13–4.74) [22]
Cohort 
study
9704 women aged >65 in 
the US
CCr 45～59mL/min
CCr＜45mL/min
CCr 45～59mL/min
CCr＜45mL/min
CCr 45～59mL/min
CCr＜45mL/min
femoral neck 1.24 (0.60–2.56)
femoral neck 1.41(0.59–3.36)
trochanter 3.69(1.21–11.24)
trochanter 5.04(1.38–18.45)
vertebra 1.08(0.61–1.92)
vertebra 1.33(0.63–2.80)
[23]
Case-
control 
study
6458 postmenopausal 
osteoporotic women in 
Canada
CCr＜45mL/min all 1.3(1.0–1.6) 
vertebra 2.5(1.6–3.9) [66]
Cohort 
study
4699 subjects aged >65 in 
the US
eGFR＜60mL/min/1.73m2
Cystatin C 1SD above
hip 1.38(0.99–1.94)
hip 1.16(1.01–1.33) [25]
Case-
control 
study
397 incident hip fracture 
cases  and 397 matched
controls in the US
eGFR＜60mL/min/1.73m2 hip 2.50(1.32–4.72) [67]
Case-
control 
study
659 postmenopausal 
women in Japan CCr  60～89mL/min vertebra 2.79(1.31–5.95) [26]
         
Table 2. Elevated fracture risk in CKD
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adjustment for years after menopause, smoking, drinking, and BMD at vertebrae (OR=0.359,
95%CI: 0.168-0.765, p=0.01). There were significant positive correlations between eGFR and
BMD at the femoral neck and the radius. These findings suggest that the reduction of BMD
and the elevation of risk for fracture may start during early CKD (eGFR<90 mL/min/1.73m2).
However, Ensrud et al. could not find a significant association of incident vertebral fractures
with kidney function calculated by C-G as well as MDRD formulas [23]. The discrepancies of
these two reports could be derived from the differences of participants’ background such as
race, age, and kidney function, and the methodology. In the latter study, 150 patients, who had
incident vertebral fractures, were relatively older (mean age: 73.1 years) than those of the
former study. In addition, the second X-ray was not performed in 22% of women possibly due
to bed rest or death. Thus, such limitation should be taken into account when the results of
prospective study are assessed.
Previous studies suggest that the risk for fracture is elevated in parallel with a decrease in
kidney function. We estimated the risk for fracture with the assessment tool FRAX® (http://
www.shef.ac.uk/FRAX/) in 1,935 community-dwelling healthy Japanese people (1,123 women
and 812 men, mean age: 68.9) [27]. Estimated risk of hip fracture for 10 years was 2.1% in men
and 4.6% in women, respectively (Figure 1), and the risk was inversely proportionate to eGFR.
Significant increase of the risk for fracture was observed in men with eGFR<60 ml/min/
1.73m2 and women with eGFR<75 ml/min/1.73m2. Major risk of osteoporotic fracture (verte‐
brae, hip, radius and humerus) for 10 years was estimated as 6.8% in men and 14.0% in women,
which was also elevated as a loss of kidney function. As we have shown the elevated risk for
fracture in CKD population using FRAX®, this tool has originally been developed for the
screening of patients with high risk for fracture. Indeed, Jamal et al. have recently reported the
utility of FRAX® in CKD patients [28]. 
**
**
*
Women
Men(%)
-90 89-75 74-60 59-
eGFR (ml/min/1.73m2)
0
1
2
3
4
5
6
7
Figure 1. Association between eGFR and 10 year-hip fracture incidence calculated by FRAX® In 1,935 community-
dwelling healthy Japanese people (1,123 women and 812 men, mean age: 68.9), association between eGFR (MDRD for‐
mula) and 10 year-hip fracture incidence calculated by FRAX® was shown. *; p<0.001and **; p<0.005 (vs eGFR 90-
ml/min/1.73m2), Post-hoc test (Fisher’s PLSD) (modified by ref. [27])
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In this part, terms such as eGFR and CCr were used followed by the original reports. Moreover,
CCr was corrected with body surface in some reports and not in others. Kidney function is
prone to be underestimated in C-G formula and overestimated in MDRD, which may lead
confusion and the discrepancy among study results as described by Ensrud et al. [23].
4. Pathophysiology of elevated risk for fracture in CKD
Low BMD is a risk for fracture in the general population, and this is also true for CKD patients
[29-32]. Recent longitudinal studies using high resolution peripheral quantitative computed
tomography (HR-pQCT) have demonstrated that loss of kidney function is associated with a
decrease in BMD, independent of age and body mass [29-32]. HR-pQCT is developed to
measure volumetric bone mass, and to discriminate between cortical bone and trabecular bone.
Volumetric BMD measured by HR-pQCT is more accurate than areal BMD by DXA, because
areal BMD depends on body size and cannot exclude aortic calcification [33]. Cejka et al.
reported the characteristics of bone microarchitecture of 74 HD patients, where cortical and
trabecular microarchitecture was significantly impaired in patients with fracture [34]. Trabec‐
ular BMD at the tibia was the strongest determinant of fracture in these patients. In 70 patients
aged ≥50 with CKD stage 2-4, trabecular BMD at the tibia and radius, trabecular number and
cortical thickness were significantly decreased and trabecular separation was increased [35].
Another study by Nickolas demonstrated a significant loss of cortical BMD at the distal radius,
and marked increase in cortical porosity without any changes in trabecular indices in CKD
patients [36]. There was a significant association between kidney dysfunction and cortical bone
loss as well as increased porosity [35]. Although DXA has a lower discriminatory power than
HR-pQCT measured volumetric density, a recent report suggests a benefit of BMD measure‐
ment even with DXA to identify HD patients with high risk of fracture [32].
Although bone histological analysis is the most accurate method, a few studies have been
reported because of its invasiveness and difficulty. Tomiyama et al. conducted bone biopsy at
the iliac crest of 50 CKD patients after tetracycline labelling [37]. Interestingly, histomorph‐
ometry showed low turnover of bone in most patients; 100% in stage 2, 88% in stage 3, and
78% in stage 4. This finding suggests that the bone formation rate is markedly depressed in
CKD at early stages.
Bone strength depends not only on BMD but also on the other factors, which have been called
as a bone quality. In primary osteoporosis, bone strength is explained about 70% by BMD and
the rest by bone quality. Since the risk for fracture is dissociated with BMD especially in
patients with DM and with glucocorticoid-induced osteoporosis, areal BMD cannot effectively
predict fracture [5-8]. This might be the case in CKD, and the factors other than BMD, such as
bone quality would play a part in bone fragility, especially in later stages of CKD. Especially
in patients with type 2 DM, bone strength is significantly decreased, while BMD tends to be
increased due to obesity. Because DM is a leading cause of ESKD, at least to some extent DM
affects risk for fracture in CKD population. Actually, previous reports demonstrated the
significant elevation of risk for fracture in ESKD patients with DM, compared to those without
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DM [38]. Pathogenesis of elevated risk for fracture in DM is explained by deteriorated bone
quality as well as increased incidence of falls. DM patients treated by insulin have 2.78 times
higher risk for falls than non-DM subjects [39]. In addition, DM is an independent risk for falls
in HD patients with OR of 2.75 [40]. Increased risk of falls in DM may be caused by impaired
neuromuscular function, increased instability, loss of vision, hypoglycemia, arthritis, cardio‐
vascular disorders, depression and medication such as hypnotics or tranquilizers. Thus, these
factors including DM should be the risks for falls and fracture in CKD patients.
Many factors are known as a risk for fracture including low BMD, factors independent of BMD
such as older age, female sex, prevalent fracture, smoking, drinking, steroid use, family history
for fracture, excise, and factors dependent of BMD such as low body weight [3, 4]. On the other
hand, in CKD patients, there may be additional factors including history of kidney transplant,
decreased 1,25(OH)2D, increased parathyroid hormone (PTH), other hormonal changes,
metabolic acidosis, uremic toxins, inflammatory cytokines, and homocysteine play a role
[41-48]. Although each occurs at different stages of CKD, all can affect the bone at the end-
stage. Bone changes can be associated with PTH and bone metabolic markers. However,
increase in serum PTH level generally starts at GFR <45mL/min. Actually, recent studies using
cystatin C demonstrated that PTH, inflammation, and bone turnover did not affect the risk for
fracture at least in early CKD [49, 50]. On the contrary, increasing evidences suggest that
fibroblast growth factor 23 (FGF23) level is elevated to suppress bone formation at CKD stage
2, which occurs at an earlier time than the increase in PTH or decrease in 1,25(OH)2D [51-53].
In addition, FGF23 may be an independent risk of vertebral fracture [54].
Bone quality is classified by material and structural properties, both of which are considered
to be altered in CKD. As for structural properties, cortical thinning, porosity, and irregular
thickness and loss of connectivity in trabecular bone have been reported [36]. On the other
hand, material properties are not well understood. Animal study shows the changes in
chemical composition of cortical bone and the deterioration in the quality of bone matrix
proteins, such as type I collagen and collagen crosslinking [55], although there is a controversy
[56]. These changes are thought to be resulted from an increase in advanced glycation end
products (AGEs) including pentosidine that causes loss of normal crosslinking; which are
mediated by high glucose, homocysteine, reactive oxygen species and low vitamin B6 [57, 58].
Therefore, both loss of bone volume and deterioration of bone quality (altered material and
structural properties at micro and macro levels) may be involved in the progression of bone
fragility in CKD. Future study is needed to elucidate the deteriorated bone quality in CKD
including functional changes in osteocytes and involvement of sclerostin, which regulates
osteoblastic activity.
At present, however, most conceivable reason for increased risk for fracture in CKD patients
is that CKD and osteoporosis have a lot of common risk factors for the pathogenesis and disease
progression (Figure 2). This fact is supported by clinical findings [20, 46]. The factors including
aging, inflammation, renin-angiotensin axis, oxidative stress, insulin resistance, hyperglyce‐
mia, AGEs, smoking, menopause, lack of exercise, homocysteine, uremic toxins, ADMA, and
FGF23 are possible common candidates. At the same time, these factors are thought to be
involved in the development of vascular calcification [46, 59-63]. In addition to the relationship
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between vascular calcification/ atherosclerosis and osteoporosis, so called bone-vascular
relationship, hypertension and chronic obstructive pulmonary disease (COPD) also become
aware of fracture risks. On the other hand, cortical bone thickness measured by HR-pQCT was
reported to be the best predictor for hip fracture in CKD patients [64]. Since bone turnover
markers such as P1NP and TRACP5b are risk factors for fracture independent of BMD in CKD
patients, combination of BMD and bone turnover markers makes it possible to discriminate
subjects with bone fragility [64]. Further studies are necessary to identify noninvasive assess‐
ment tools for fracture risk.
CKD‐MBD
Normal Vessels
Vascular Calcification
/Risk of CVD
Normal Kidney
CKD/ESKD
Normal Bone
Osteoporosis
/Risk of fracture
Loss of bone strength
(loss of bone mass and 
deteriorated bone quality)
Common 
Risk Factors
Medial Calcification
(osteoblastic changes of 
vascular smooth muscle cells)
Figure 2. Mechanisms of elevated risk for fracture in CKD patients. Although precise mechanisms remain uncertain,
CKD and osteoporosis have many common risk factors, and in addition, CKD progression is associated with increased
risk for fracture probably due to bone loss as well as deterioration of bone quality. Aging, inflammation, renin-angio‐
tensin axis, oxidative stress, insulin resistance, hyperglycemia, AGEs, smoking, menopause, lack of exercise, homocys‐
teine, uremic toxins, ADMA, and FGF23 are possible candidates for the common factors, and at the same time, these
are thought to be involved in the development of vascular calcification.
5. Conclusion
CKD is not a single disease but a kind of syndrome. Thus, hypertension, obesity, atheroscle‐
rosis, gout, nephrolithiasis and life style are highly linked to the pathogenesis and the
development of CKD. Diabetic nephropathy and hypertensive nephropathy are commonly
observed in CKD, and these are probably at high risk for fracture. Because prevalence of CKD
and osteoporosis increases in parallel with age, aged people often suffer from both disorders.
Nowadays, CKD has been established as a risk factor for fragility fracture independent of age
Updates in Hemodialysis84
and BMD. Not only CKD progression but also bone loss is associated with mortality [61-63].
Thus, bone should be cared in early stages of CKD, at least followed by guidelines [42, 65].
Since bisphosphonates are not recommended in ESKD patients, future work is necessary to
establish treatment of osteoporosis or osteopenia complicated with ESKD.
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